Periotherapia closes US$4.42M Series D2 to push pathological-periostin antibody into North America
What's the deal? Periotherapia, a drug-development startup spun out of Osaka University, has closed a Series D2 round totalling US$4.42M (roughly $4M). The round combined equity — via J-KISS convertible notes issued to Mitsubishi UFJ CapitalDealroom has a profile for this one. Try Dealroom →'s life-science fund and Techno ScienceDealroom has a profile for this one. Try Dealroom → Co. — with bank debt. On top of the raise, the company holds up to US$8.31M in grants from Japan's national medical research agency AMEDDealroom has a profile for this one. Try Dealroom →, bringing total fresh resources above US$12.3M. Cumulative equity funding now exceeds US$18.5M.
Why now? Periotherapia is developing PT0101, an antibody drug that targets a mutant form of the protein periostin linked to treatment-resistant HER2-negative breast cancer. It is already running a Phase 1/2a trial in Japan and plans to launch the same study in North America — a step that demands significant capital.
The AMED grant, awarded under a programme designed to strengthen Japan's biotech venture ecosystem, gives the company room to stretch private capital further. CEO Eiji Tahara said the combined US$12.3M-plus war chest will "accelerate global clinical development, including in North America."
Mitsubishi UFJ Capital, which has backed Periotherapia since its Series A, said it remains confident in the drug's potential to reach patients.
The signal: Periotherapia is leaning heavily on AMED's ecosystem-strengthening programme to complement Japan's comparatively shallow biotech venture market — its US$8.31M grant is nearly twice the size of the US$4.42M private round. Mitsubishi UFJ Capital's continued backing since Series A signals sustained domestic conviction, but the modest round size highlights how far Japanese university spinouts still have to go to match the war chests of US oncology peers tackling drug-resistant cancers.
Read more: PR TIMES
